glp 1 and osteoporosis GLP-1 Therapy Associated with Lower Fracture Risk in Patients with Bone Density Disorders GLP-1 weight loss drug study

Importantly, the metabolic consequences of GLP-1RA therapy arise not only from appetite suppression but also from sustained GLP-1R signaling under conditions of chronically reduced nutrient inflow

Contraindication Signals Standard conservative practice excludes anyone with active gastrointestinal disease, type 1 diabetes, prior pancreatitis, medullary thyroid carcinoma history, or active cancer from any tirzepatide protocol

Mast cell activation should be a consideration if symptoms from foods / drinks come within a few minutes to 15 minutes come on

It doesn't matter where they come from

Neither route has human clinical trial evidence